News
Public · Published
GE HealthCare's (NASDAQ:GEHC) Q3 2026 sales beat estimates
GE HealthCare reported Q3 2026 revenue of $5.51 billion, up 7.2% from a year earlier and above analysts' consensus estimate of $5.35 billion. Non-GAAP profit was $1.34 per share, 11.3% above consensus, and the company raised full-year adjusted EPS guidance to $5 at the midpoint.
Published:
Updated:
What happened
GE HealthCare reported Q3 2026 revenue of $5.51 billion, up 7.2% from a year earlier and above analysts' consensus estimate of $5.35 billion. Non-GAAP profit was $1.34 per share, 11.3% above consensus, and the company raised full-year adjusted EPS guidance to $5 at the midpoint.
Confirmed
Global impact / market context
Higher revenue and a 14.6% operating margin, up from 12.7%, mean GE HealthCare kept more profit from each sale. Raised guidance signals management expects this momentum to continue, which can support investor confidence in future earnings.
Analyst inference
A revenue beat alongside margin expansion suggests demand for healthcare technology held up and cost discipline improved. Because the company also lifted its full-year profit outlook, the results point to stronger expected earnings rather than one-off gains.
Analyst inference
What to watch
- Full-year adjusted EPS guidance was raised to $5 at the midpoint, a 2% increase, so future results should be compared against this updated target. Confirmed
- Watch whether operating margin stays near 14.6% in coming quarters, since holding more profit per sale is what turned revenue growth into stronger earnings. Analyst inference
- Watch free cash flow margin, which rose to 14.4% from 9.4%, because more cash available funds research, debt payments, or shareholder returns. Analyst inference